Integrated BioPharma, Inc.
INBP · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.12 | 2.88 | -0.07 |
| FCF Yield | 17.33% | 6.49% | 11.29% | 24.16% |
| EV / EBITDA | 2.43 | 4.17 | 8.82 | 4.68 |
| Quality | ||||
| ROIC | 3.60% | 0.48% | -0.18% | 14.08% |
| Gross Margin | 10.23% | 7.72% | 8.01% | 11.65% |
| Cash Conversion Ratio | 2.56 | 8.42 | -36.24 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.37% | -3.64% | -7.27% | 2.15% |
| Free Cash Flow Growth | 380.51% | -65.05% | -69.04% | 30.85% |
| Safety | ||||
| Net Debt / EBITDA | -0.77 | 0.08 | 1.06 | 0.48 |
| Interest Coverage | 43.91 | 4.83 | 3.00 | 18.37 |
| Efficiency | ||||
| Inventory Turnover | 5.21 | 4.13 | 4.54 | 4.50 |
| Cash Conversion Cycle | 89.54 | 102.52 | 95.10 | 89.35 |